3 beta-hydroxy-delta 5-cholenic acid, also known as cholic acid, is a primary bile acid synthesized in the liver from cholesterol. It plays a crucial role in fat digestion and absorption by emulsifying dietary fats in the small intestine. Cholic acid is also involved in the regulation of cholesterol metabolism and the detoxification of harmful substances. Its synthesis, effects, and importance are extensively studied to understand its role in human health and to develop therapeutic strategies for conditions like gallstones, liver disease, and cholesterol disorders.'
| ID Source | ID |
|---|---|
| PubMed CID | 92997 |
| CHEMBL ID | 169264 |
| CHEBI ID | 89234 |
| SCHEMBL ID | 1219702 |
| MeSH ID | M0063245 |
| Synonym |
|---|
| cholenic acid |
| (4r)-4-[(1s,2r,5s,10s,11s,14r,15r)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-7-en-14-yl]pentanoic acid |
| bdbm20190 |
| 3beta-hydroxy-chol-5-en-24-oic acid |
| LMST04010201 |
| 3b-hydroxy-5-cholenoic acid |
| 5-cholenic acid-3beta-ol |
| CHEMBL169264 |
| chebi:89234 , |
| 5255-17-4 |
| H0521 |
| 3beta-hydroxy-delta5-cholenic acid |
| (4r)-4-[(3s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| 3beta-hydroxychol-5-en-24-oic acid |
| 3beta-hydroxy-5-cholenic acid |
| 3beta-hydroxy-5-cholenoic acid |
| S6481 |
| SCHEMBL1219702 |
| chol-5-en-24-oic acid, 3-hydroxy-, (3b)- |
| 5-cholenic acid-3.beta.-ol |
| 3.beta.-hydroxy-5-cholen-24-oic acid |
| 3-.beta.-hydroxy-5-cholenic acid |
| HIAJCGFYHIANNA-QIZZZRFXSA-N |
| chol-5-en-24-oic acid, 3-hydroxy-, (3.beta.)- |
| 3-beta-hydroxycholenic acid |
| 3-beta-hydroxy-delta-(5)-cholenic acid |
| AS-61758 |
| 3b-hydroxycholenoic acid |
| d5-cholenic acid |
| 3b-hydroxychol-5-en-24-ic acid |
| 3b-hydroxychol-5-en-24-oic acid |
| 3b-hydroxy-chol-5-en-24-oate |
| 3b-hydroxy-5-cholenoate |
| 3b-hydroxychol-5-en-24-ate |
| 3beta-hydroxy-5-cholenoate |
| 3b-hydroxychol-5-en-24-oate |
| d5-cholenate |
| 3b-hydroxychol-5-enoate |
| 3b-hydroxychol-5-enoic acid |
| 3b-hydroxy-chol-5-en-24-oic acid |
| 3b-hydroxycholenoate |
| cholenate |
| 3beta-hydroxychol-5-en-24-oate |
| Q27161420 |
| (r)-4-((3s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoic acid |
| 3beta-hydroxy-delta5-cholenicacid |
| HY-113315 |
| CS-0059579 |
| DTXSID901317558 |
| (4r)-4-[(1r,3as,3bs,7s,9ar,9bs,11ar)-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl]pentanoic acid |
| EN300-7411336 |
| EVD67Y26MR |
| chol-5-en-24-oic acid, 3-hydroxy-, (3beta)- |
| delta5-3beta-hydroxycholenic acid |
| zinc-04831336 |
| delta5-cholenic acid |
| 3beta-hydroxychol-5-en-24-ic acid |
| hydroxy-5-cholenic acid, 3beta- |
| (3beta)-3-hydroxychol-5-en-24-oic acid |
| Class | Description |
|---|---|
| steroid | Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Ephrin type-A receptor 2 | Homo sapiens (human) | IC50 (µMol) | 39.8107 | 0.0008 | 0.0436 | 0.2626 | AID1260952 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Oxysterols receptor LXR-alpha | Homo sapiens (human) | EC50 (µMol) | 3.0000 | 0.0001 | 0.6302 | 6.7100 | AID101835; AID1797959 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID101844 | Tested for its ability to activate Liver X receptor-alpha expressed as Relative efficacy determined by maximal increase in relative fluorescence in LiSA | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6 | Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha. |
| AID1179741 | Binding affinity to FLAG/tGFP-tagged NPC1 I1061T mutant (unknown origin) expressed in HEK293 cells assessed as localization at 10 uM after 24 hrs by fluorescence microscopy | 2014 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15 | Structure-activity relationships of oxysterol-derived pharmacological chaperones for Niemann-Pick type C1 protein. |
| AID662387 | Inhibition of STAR in mouse MA-10 cells assessed as inhibition of dbcAMP-stimulated cholesterol synthesis at 10 uM after 2 hrs by RIA | 2012 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12 | Identification of small-molecule inhibitors of the steroidogenic acute regulatory protein (STARD1) by structure-based design. |
| AID101835 | Concentration required for half maximal activity was calculated in human nuclear oxysterol receptor liver X receptor-alpha in LiSA. | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6 | Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha. |
| AID768322 | Binding affinity to human GFP-tagged NPC1L1 L1072T/L1168I mutant expressed in HEK293 cells assessed as localization to endoplasmic reticulum and plasma membrane after 24 hrs by fluorescence microscopic analysis | 2013 | Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17 | Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect. |
| AID1260952 | Displacement of biotinylated-ephrin-A1-Fc from EphA2-Fc receptor (unknown origin) preincubated for 1 hr followed by biotinylated-ephrin-A1-Fc addition measured after 4 hrs by ELISA | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Δ(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. |
| AID1797959 | Cell-Free Ligand Sensing Assay (LiSA)-LXRalpha-SRC1 Assay from Article 10.1021/jm0004749: \\Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha.\\ | 2001 | Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6 | Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||